Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095108 · ClinicalTrials.gov registry record · Phase 1
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
A Phase 1 study, sponsored by ZymoGenetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00095108: Completed Phase 1 study, sponsored by ZymoGenetics.
NCT00095108 is a Phase 1 study that has completed, run by ZymoGenetics. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095108, a Phase 1 study, has completed, sponsored by ZymoGenetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.
Interventions
- DRUG Recombinant Human Interleukin-21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
What the finished NCT00095108 record still lists
NCT00095108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Interleukin-21 is the first listed.
NCT00095108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00095108 about?
NCT00095108 is a clinical study titled "Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer". This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.
What is the current status of trial NCT00095108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2004-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00095108?
The interventions under investigation include: Recombinant Human Interleukin-21 (DRUG).
Who is sponsoring clinical trial NCT00095108?
This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00095108's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia